Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 2 (1)

Trial Status

Not Yet Recruiting3
Recruiting2
Enrolling By Invitation1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07655102Not Yet RecruitingPrimary

Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome

NCT07364656Not ApplicableNot Yet RecruitingPrimary

Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors

NCT02413450Enrolling By Invitation

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

NCT07146880Phase 2Not Yet RecruitingPrimary

Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

NCT06988189Recruiting

Unmasking Concealed Arrhythmia Syndromes

NCT06647927RecruitingPrimary

GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis

Showing all 6 trials

Research Network

Activity Timeline